{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T04:51:17Z","timestamp":1770526277368,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s12325-015-0276-3","type":"journal-article","created":{"date-parts":[[2016,1,2]],"date-time":"2016-01-02T06:34:40Z","timestamp":1451716480000},"page":"46-57","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Utilization of Subcutaneous Methotrexate in Rheumatoid Arthritis Patients After Failure or Intolerance to Oral Methotrexate: A Multicenter Cohort Study"],"prefix":"10.1007","volume":"33","author":[{"given":"Jaime C.","family":"Branco","sequence":"first","affiliation":[]},{"given":"Anabela","family":"Barcelos","sequence":"additional","affiliation":[]},{"given":"Filipe Pombo","family":"de Ara\u00fajo","sequence":"additional","affiliation":[]},{"given":"Gra\u00e7a","family":"Sequeira","sequence":"additional","affiliation":[]},{"given":"In\u00eas","family":"Cunha","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Vaz","family":"Patto","sequence":"additional","affiliation":[]},{"given":"Margarida","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Margarida Pratas","family":"Mateus","sequence":"additional","affiliation":[]},{"given":"Maura","family":"Couto","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcia","family":"Nero","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcia","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Paulo","family":"Monteiro","sequence":"additional","affiliation":[]},{"given":"Walter","family":"Castel\u00e3o","sequence":"additional","affiliation":[]},{"given":"Jorge","family":"F\u00e9lix","sequence":"additional","affiliation":[]},{"given":"Diana","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"Maria Jo\u00e3o","family":"Silva","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2016,1,2]]},"reference":[{"key":"276_CR1","doi-asserted-by":"crossref","unstructured":"ACRSRAG: American College of Rheumatology Subcommittee on rheumatoid arthritis guidelines. Guidelines for the management of rheumatoid arthritis\u20142002 update. Arthritis Rheum. 2002;46(2):328\u201346.","DOI":"10.1002\/art.10148"},{"key":"276_CR2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Landew\u00e9 R, Breedveld F, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492\u2013509.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"276_CR3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.23144","volume":"58","author":"J Braun","year":"2008","unstructured":"Braun J, K\u00e4stner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicentre, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58(1):73\u201381.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"276_CR4","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s00393-012-1038-0","volume":"71","author":"K Kr\u00fcger","year":"2012","unstructured":"Kr\u00fcger K, Wollenhaupt J, Albrecht K, et al. German guidelines for the sequential medical treatment of rheumatoid arthritis 2012: adapted EULAR recommendations and update of a treatment algorithm [S1-Leitlinie der DGRh zur sequenziellen medikament\u00f6sen Therapie der rheumatoiden Arthritis 2012: adaptierte EULAR Empfehlung und aktualisierter Therapiealgorithmus]. Z Rheumatol. 2012;71(7):592\u2013603.","journal-title":"Z Rheumatol"},{"key":"276_CR5","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/annrheumdis-2014-205228","volume":"73","author":"MH Schiff","year":"2014","unstructured":"Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses\u00a0\u226515\u00a0mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014;73:1549\u201351.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"276_CR6","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/ard.2003.011593","volume":"63","author":"J Wegrzyn","year":"2004","unstructured":"Wegrzyn J, Adeleine P, Miossec P. Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis. 2004;63(10):1232\u20134.","journal-title":"Ann Rheum Dis"},{"key":"276_CR7","doi-asserted-by":"crossref","unstructured":"Bykerk VP, Akhavan P, Hazlewood GS, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol. 2012;39(8):1559\u201382.","DOI":"10.3899\/jrheum.110207"},{"issue":"3","key":"276_CR8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Landew\u00e9 R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. 2013 update. Ann Rheum Dis. 2014;73(3):492\u2013509.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"276_CR9","first-page":"385","volume":"36","author":"JE Fonseca","year":"2011","unstructured":"Fonseca JE, Bernardes M, Canhao H, et al. Portuguese guidelines for the use of biological agents in rheumatoid arthritis\u2014October 2011 update. Acta Reumatol Port. 2011;36(4):385\u20138.","journal-title":"Acta Reumatol Port"},{"key":"276_CR10","first-page":"276","volume-title":"2nd international symposium on information theory","author":"H Akaike","year":"1973","unstructured":"Akaike H. Information theory as an extension of the maximum likelihood principle. In: Petrov BN, Csaki F, editors. 2nd international symposium on information theory. Budapest: Akademiai Kiado; 1973. p. 276\u201381."},{"issue":"1","key":"276_CR11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1759720X11431004","volume":"4","author":"F Striesow","year":"2012","unstructured":"Striesow F, Brandt A. Preference, satisfaction and usability of subcutaneously administered methotrexate for rheumatoid arthritis or psoriatic arthritis: results of a postmarketing surveillance study with a high-concentration formulation. Ther Adv Musculoskel Dis. 2012;4(1):3\u20139.","journal-title":"Ther Adv Musculoskel Dis"},{"issue":"3","key":"276_CR12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/1759720X11408635","volume":"3","author":"J Braun","year":"2011","unstructured":"Braun J. Methotrexate: optimizing the efficacy in rheumatoid arthritis. Ther Adv Musculoskel Dis. 2011;3(3):151\u20138.","journal-title":"Ther Adv Musculoskel Dis"},{"issue":"1","key":"276_CR13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"FC Breedveld","year":"2006","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF, et al. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26\u201337.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"276_CR14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/art.25053","volume":"62","author":"P Garnero","year":"2010","unstructured":"Garnero P, Thompson E, Woodworth T, Smolen JS. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum. 2010;62(1):33\u201343.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"276_CR15","first-page":"2077","volume":"29","author":"SJ Carmichael","year":"2002","unstructured":"Carmichael SJ, Beal J, Day RO, Tett SE. Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. J Rheumatol. 2002;29(10):2077\u201383.","journal-title":"J Rheumatol"},{"issue":"7","key":"276_CR16","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/1529-0131(199907)42:7<1322::AID-ANR4>3.0.CO;2-P","volume":"42","author":"ME Weinblatt","year":"1999","unstructured":"Weinblatt ME, Kremer JM, Coblyn JS, et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum. 1999;42(7):1322\u20138.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"276_CR17","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/anr.1780320916","volume":"32","author":"JB Shiroky","year":"1989","unstructured":"Shiroky JB, Watts CS, Neville C. Combination methotrexate and sulfasalazine in the management of rheumatoid arthritis: case observations. Arthritis Rheum. 1989;32(9):1160\u20134.","journal-title":"Arthritis Rheum"},{"key":"276_CR18","first-page":"207","volume":"47","author":"L Rutkowska-Sak","year":"2009","unstructured":"Rutkowska-Sak L, Rell-Bakalarska M, Lisowska B. Oral vs. subcutaneous low-dose methotrexate treatment in reducing gastrointestinal side effects. Reumatologia. 2009;47:207\u201311.","journal-title":"Reumatologia"},{"issue":"22","key":"276_CR19","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","volume":"343","author":"JM Bathon","year":"2000","unstructured":"Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343(22):1586\u201393.","journal-title":"N Engl J Med"},{"key":"276_CR20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/rheumatology\/keh512","volume":"44","author":"AJ Kinder","year":"2005","unstructured":"Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology. 2005;44:61\u20136.","journal-title":"Rheumatology"},{"issue":"2","key":"276_CR21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pr.57.2.3","volume":"57","author":"BN Cronstein","year":"2005","unstructured":"Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005;57(2):163\u201372.","journal-title":"Pharmacol Rev"},{"key":"276_CR22","doi-asserted-by":"crossref","unstructured":"Genovese, MC, Bathon JM, Martin RW et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002;46(6):1443\u201350.","DOI":"10.1002\/art.10308"},{"issue":"7","key":"276_CR23","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/art.1780290702","volume":"29","author":"JM Kremer","year":"1986","unstructured":"Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum. 1986;29(7):822\u201331.","journal-title":"Arthritis Rheum"},{"key":"276_CR24","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","volume":"359","author":"HK Choi","year":"2002","unstructured":"Choi HK, Hern\u00e1n MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359:1173\u20137.","journal-title":"Lancet"},{"issue":"3","key":"276_CR25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/03009740410005467","volume":"33","author":"R Rau","year":"2004","unstructured":"Rau R, Simianer S, van Riel PL, et al. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate. Scand J Rheumatol. 2004;33(3):145\u201353.","journal-title":"Scand J Rheumatol"},{"key":"276_CR26","first-page":"11","volume":"34","author":"C Neves","year":"2009","unstructured":"Neves C, Jorge R, Barcelos A. A teia de toxicidade do metotrexato. Acta Reumatol Port. 2009;34:11\u201334.","journal-title":"Acta Reumatol Port"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-015-0276-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T03:58:15Z","timestamp":1567483095000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-015-0276-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["276"],"URL":"https:\/\/doi.org\/10.1007\/s12325-015-0276-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}